Pathogen News and Research

RSS

VBI researchers receive grant to study immune responses to gut pathogens

The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has awarded a $10.6 million grant to researchers at the Virginia Bioinformatics Institute (VBI) and collaborators to determine how the human immune system responds to infection by pathogens of the gut. The funding will be used to apply mathematical modeling to the study of immune responses to gut pathogens.

11 Oct 2010

Scientists proves Yersinia pestis as causative agent for Black Death epidemics in European continent

The latest tests conducted by anthropologists at the Johannes Gutenberg University Mainz (JGU) have proven that the bacteria Yersinia pestis was indeed the causative agent behind the "Black Death" that raged across Europe in the Middle Ages. The cause of the epidemic has always remained highly controversial and other pathogens were often named as possible causes, in particular for the northern European regions.

11 Oct 2010

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Many drug-resistant infections are the result of bacterial biofilms, structured aggregates of bacteria that live on surfaces and that are extremely resistant to environmental stresses. These biofilms impact human health in many ways - cystic fibrosis, for example, is a disease in which patients die from airway bacterial biofilm infections that are invulnerable to even the most potent antibiotics.

11 Oct 2010

IntegenX receives DTRA contract to develop ISS system for rapid detection of emerging pathogens

IntegenX, Inc. today announced that it has been awarded a new contract by the Defense Threat Reduction Agency (DTRA) of the U.S. Department of Defense (DoD) to develop an Integrated Sample-to-Sequence (ISS) system for rapid detection and identification of genetically engineered bacteria and viruses, medically relevant bacteria and viruses, and emerging pathogens.

11 Oct 2010

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Arlington Medical Resources (AMR), a provider of premier market intelligence for the pharmaceutical and diagnostic imaging industries, finds that methicillin-resistant Staphylococcus aureus (MRSA) is the most concerning pathogen to surveyed U.S. physicians with regard to their treatment of skin and skin structure infections.

8 Oct 2010

Paper describes new method for studying bacterial infection of orthopedic implants

A research team, co-headed by Dr. Woo Lee and Dr. Hongjun Wang of Stevens Institute of Technology, has published a paper describing a new method that generates three-dimensional tissue models for studying bacterial infection of orthopedic implants. Dr. Joung-Hyun Lee of Stevens, and Dr. Jeffrey Kaplan of the New Jersey Dental School, are co-authors of the research.

7 Oct 2010

NIH awards $4 million grant to develop novel genetic strategy for combating tuberculosis

William R. Jacobs, Jr., Ph.D., professor of microbiology & immunology and of genetics at Albert Einstein College of Medicine of Yeshiva University, who is also a Howard Hughes Medical Institute (HHMI) investigator, has been awarded a three-year, $4 million grant from the National Institutes of Health to develop a novel genetic strategy for combating tuberculosis (TB). TB causes almost two million deaths each year, making it the world's most deadly bacterial infection.

5 Oct 2010

Scientist discovers novel pathogen from Mycobacterium tuberculosis complex

Kathleen Alexander, associate professor of wildlife in Virginia Tech's College of Natural Resources and Environment, has discovered a novel tuberculosis (TB) species in the Mycobacterium tuberculosis complex, a group of pathogens that have adapted by using mammals as hosts. It has been nearly two decades since a new organism was identified in this group; the majority were discovered in the early and mid 20th century.

3 Oct 2010

ASU receives grant to unravel membrane proteins in host-pathogen interaction

Arizona State University has been awarded a $7.7 million grant for the next five years from the National Institute of General Medical Sciences, part of the National Institutes of Health, to unravel the structures of membrane proteins that play a key role in protection against infectious diseases.

30 Sep 2010

Quick-Med to present abstracts on antimicrobial technologies at Clinical Symposium

Quick-Med Technologies, Inc.a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today its NIMBUS and Stay Fresh antimicrobial technologies will be highlighted at the 2010 Clinical Symposium on Advances in Skin and Wound Care, to be held in Orlando, Florida from September 30 – October 3, 2010.

29 Sep 2010

Early initiation of ART may prevent immune system damage in HIV patients: Study

HIV-infected individuals who begin antiretroviral therapy (ART) soon after acquiring the virus may have stronger immune responses to other pathogens than HIV-infected individuals who begin ART later, a new study from the National Institutes of Health has found. This finding suggests that early initiation of ART may prevent irreversible immune system damage and adds to the body of evidence showing significant health benefits from early ART.

29 Sep 2010

GBS pathogen suppresses immune cell function in newborn infants: Research

Group B Streptococcus (GBS), a bacterial pathogen that causes sepsis and meningitis in newborn infants, is able to shut down immune cell function in order to promote its own survival, according to researchers at the University of California, San Diego School of Medicine and the Skaggs School of Pharmacy and Pharmaceutical Sciences.

27 Sep 2010

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

Cerus Corporation announced today that it has received an additional $1.4 million from the U.S. Department of Defense to support advanced development of the company's pathogen inactivation technology for red blood cells. The INTERCEPT red blood cell system is a pathogen inactivation product Cerus is developing to prevent the transmission of infectious diseases through red blood cell transfusions.

24 Sep 2010

AJMS journal provides research update on new infectious pathogens

Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens.

24 Sep 2010

Scientists develop humanized mouse model to study typhoid fever

Better treatments and prevention for typhoid fever may emerge from a laboratory model that has just been developed for the disease. The model is based on transplanting human immune stem cells from umbilical cord blood into mice that are susceptible to infections.

23 Sep 2010

Researchers to develop vaccine for plague

Given the many pressing concerns of the day, fear of plague probably isn't what causes most Americans to lose sleep. But for those whose responsibility it is to combat bioterrorism, plague is among the highest priorities. Those charged with that mission include scientists like medical researcher Steve Smiley, whose lab at the Trudeau Institute is working to develop a vaccine that will protect the public against weaponized forms of plague.

21 Sep 2010

Study suggests older people may not benefit from new tuberculosis vaccines

Elderly people might not benefit from some of the tuberculosis vaccines currently in development, recent research suggests.Some vaccines under study are designed to activate a specific molecule that is an early participant in the immune response against TB in young people. But a recent Ohio State University study suggests that in older people, this molecule remains relatively inactive, even in the face of TB infection.

21 Sep 2010

New anti-pathogenic drugs render MRSA harmless without killing bacteria

Menachem Shoham, PhD, associate professor and researcher in the department of biochemistry at the Case Western Reserve University School of Medicine, has identified new anti-pathogenic drugs that, without killing the bacteria, render Methicillin Resistant Staphylococcus Aureus (MRSA) harmless by preventing the production of toxins that cause disease.

17 Sep 2010

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today participated in the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy

16 Sep 2010

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Pathogen News and Research

VBI researchers receive grant to study immune responses to gut pathogens

Scientists proves Yersinia pestis as causative agent for Black Death epidemics in European continent

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

IntegenX receives DTRA contract to develop ISS system for rapid detection of emerging pathogens

MRSA pathogen influences U.S. physician drug selection for treating skin structure infections

Paper describes new method for studying bacterial infection of orthopedic implants

NIH awards $4 million grant to develop novel genetic strategy for combating tuberculosis

Scientist discovers novel pathogen from Mycobacterium tuberculosis complex

ASU receives grant to unravel membrane proteins in host-pathogen interaction

Quick-Med to present abstracts on antimicrobial technologies at Clinical Symposium

Early initiation of ART may prevent immune system damage in HIV patients: Study

GBS pathogen suppresses immune cell function in newborn infants: Research

Cerus receives $1.4 million to support development of INTERCEPT red blood cell system

AJMS journal provides research update on new infectious pathogens

Scientists develop humanized mouse model to study typhoid fever

Researchers to develop vaccine for plague

Study suggests older people may not benefit from new tuberculosis vaccines

New anti-pathogenic drugs render MRSA harmless without killing bacteria

Advanced Life Sciences participates as exhibitor in 50th ICAAC

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Best practices - optimize qPCR processes for pathogen detection eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics